Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, and Innovative Molecules GmbH (“Innovative Molecules”), a clinical-stage biotechnology company, today announced a strategic partnership ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the most undervalued blue chip stocks to buy now.

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works. The discovery sheds light on an important tool for fighting drug-resistant ...

Study uncovers key insights about how a new class of antiviral drugs works. Cryo-EM images showed the drugs bound to herpes simplex virus (HSV) protein at nearly atomic detail, while optical tweezers ...

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works. The discovery sheds light on an important tool for fighting drug-resistant ...

Foster City: Gilead Sciences and Assembly Biosciences have announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Genital herpes, caused by HSV, is a chronic ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 22, 2025-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has ...